288 / 1851
5FU/CDDP
±
Cetuximab:
SCOPE Trial
Phase II/III trial:
RT-CT: Cisplatin 60 mg/m2 D1+ capecitabine: 625mg/m2 twice daily
4 cycles – RT 50 Gy during cycles 3&4
±
Cetuximab: 400 mg/m2 D1 then 250 mg/m2 weekly
Crosby, Lancet Oncol 2013; 14: 627–37